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FibrillogenesisA variety of peptides and peptide derivatives have been constructed using the ‘‘b-sheet core
segment’’ of amyloid proteins as inhibitors of amyloidogenic ﬁbrillation. A novel all-D-amino-acid
from hIAPP b-sheet core segment (hIAPP 22–27) is demonstrated to inhibit hIAPP ﬁbril formation
efﬁciently both at the phospholipid membrane and in bulk solution. The inhibitor terminates hIAPP
aggregation to the a-helical oligomeric intermediates at the membrane surface, whereas it stops the
aggregation at the stage of b-sheet oligomeric intermediates in bulk solution. This is the ﬁrst
evidence that the inhibition mechanism of the inhibitor at membrane surface is signiﬁcantly
different from that in bulk solution.
Structured summary of protein interactions:
hIAPP and hIAPP bind by transmission electron microscopy (View interaction)
hIAPP and hIAPP bind by atomic force microscopy (View interaction)
hIAPP and hIAPP bind by ﬂuorescence technology (View interaction)
hIAPP and hIAPP bind by dynamic light scattering (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction hIAPP binds strongly to lipid membranes [13–19], in particular toAmyloid deposit of human islet amyloid polypeptide (hIAPP) in
pancreatic islets is closely associated with the pathology of type 2
diabetes by promoting pancreatic b-cell death [1–4]. Therefore,
preventing hIAPP ﬁbrillogenesis has been a primary strategy in
development of therapeutic drugs for type 2 diabetes [5] and
related studies have attracted much attention of researchers.
Quite abundant hIAPP amyloidogenic inhibitors including small
molecules and synthetic peptides have been tested by characteriz-
ing their activity and mechanism of inhibition of ﬁbril formation in
previous studies. Whereas most of the studies were performed in
bulk solution [6–9], few works were done at membrane surfaces
[10–12]. However, compared with the study in bulk solution, the
study at lipid membrane interface should be more important
because hIAPP-induced toxicity in diabetes involves interactions
between the cell membrane and misfolded protein. Many studies
using phospholipids as model membranes have demonstrated thatanionic membranes [18,20]. Moreover, the activity and mechanism
of inhibition at membrane interface may be quite different from
those in bulk solution. The interaction of hIAPP with membranes
could hinder access of some inhibitors to the binding site of the
amyloid protein and reduce the efﬁciency of these inhibitors.
Therefore, the effect of membranes on the interactions of inhibitors
with amyloid peptides, which was largely ignored in previous
studies, should be considered in designing and testing amyloid
peptide inhibitors. Otherwise, it could lead to an incorrect evalua-
tion to the performance of some inhibitors and misleading to inhi-
bition mechanism. The latest study demonstrated that a promising
inhibitor of amyloid ﬁbrils ()-epigallocatechin gallate (EGCG) has
a strongly reduced efﬁciency to inhibit the formation of hIAPP
amyloid ﬁbrils at phospholipid interface in contrast to its behavior
in bulk solution [12].
An on-pathway mechanism which begins from random coils to
ordered b-sheet binding ﬁbrils via a variety of intermediates,
including transiently a-helix-folded monomers, a-helical
oligomers, b-sheet binding oligomers, has been suggested for
self-assembly of amyloid peptides [18,21–28]. The design of the
inhibitors speciﬁcally targeting one of these types of intermediates
could be very signiﬁcant but also rather difﬁcult. Till now, the
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unknown. A speciﬁc trapping of intermediates by inhibitors could
depend on the lifetime of the intermediates, the property of the
inhibitors, the environments where amyloid proteins are involved,
etc. The a-helix-containing intermediates seem particularly impor-
tant for amyloid formation at membrane interfaces [25]. The stabi-
lizing effect of membrane on a-helical conformations of amyloid
peptides could extend the lifetime of a-helices at membrane
surfaces, providing a possibility to inhibit ﬁbril formation by
arresting the a-helix-containing intermediates if the intermediates
are on-pathway.
The C-terminal region of hIAPP was recognized to include self-
recognition motifs for amyloid ﬁbril formation of the protein. The
short peptides directly truncated [29] or rationally modiﬁed
[7,30] from different parts of the region have been tested to inhibit
hIAPP amyloidogenesis. The segment hIAPP 22–27 (NFGAIL) was
proposed to participate in the formation of b-sheet structures in
hIAPP ﬁbrillation and could form ﬁbrils with typical amyloid ﬁbril
morphology by itself [31,32]. However, unmodiﬁed NFGAIL does
not display inhibitory activity to hIAPP amyloidogenesis and cyto-
toxicity, and even enhances ﬁbrillation [33]. Interestingly, the
inhibitory efﬁciency can be activated after N-methyl is introduced
at two selected amide bonds within the short peptide [11,30], sug-
gesting a possibility of designing hIAPP amyloid ﬁbril inhibitors by
modiﬁcation of the core sequence NFGAIL. The substitution of
all-D-amino-acids for the peptide segment may be one of
approaches. The potency of all-D-amino-acids as inhibitor against
ﬁbril formation has been conﬁrmed by the investigations of Ab
peptides [34–36]. Moreover, the all-D-amino-acid inhibitors are
resistant to proteolytic degradation [37,38] and usually less
immunogenic [39].
In the current study, we used an all-D-amino-acid substituent of
NFGAIL (hIAPP 22–27) as inhibitor to probe its potency and mech-
anism in preventing ﬁbril formation of hIAPP both in bulk solution
and at membrane surface by monitoring the dynamic processes,
size distribution, structure details and morphologies of hIAPP
aggregation in the absence and presence of the inhibitor.2. Materials and methods
2.1. Materials
The hIAPP with an amidated C-terminus and an oxidized disul-
ﬁde between Cys2 and Cys7 was synthesized by Shanghai Science
Peptide Biological Technology Co., Ltd with the purity higher than
95%. The short peptide composed of all-D-amino-acids, D-NFGAIL,
with purity higher than 95% was purchased from GL Biochem
(Shanghai) Ltd. The phospholipids 1-palmitoyl-2-oleoyl-sn-glyce-
ro-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glyce-
ro-3-phospho-(10-rac-glycerol) (POPG) was purchased from
Avanti Polar Lipids. Other chemical agents were obtained from Sig-
ma–Aldrich. The peptides and chemical agents were used as
purchased without further treatment.
2.2. Preparation of solutions
Synthetic hIAPP was dissolved in 1,1,1,3,3,3-hexaﬂuoro-2-iso-
propanol (HFIP) solution at a concentration of 1 mg/ml. The
solution was sonicated in water bath for 5 min to break up any
pre-existing aggregates and then lyophilized. The freeze-dried pep-
tide powder was hydrated in 60 lL Milli-Q water at 4 C to a
concentration of 1 mg/ml immediately prior to use. The solution
of all-D-amino-acid inhibitor was freshly prepared in buffer before
each experiment. A 25 mM phosphate buffer at pH 7.4 with 25 mM
NaCl was prepared and used for all experiments.2.3. Preparation of small unilamellar vesicles
Phospholipids POPC and POPG were dissolved according to the
molar ratio of POPC:POPG 7:3 in chloroform/methanol mixture of
2:1 and dried under a dry nitrogen ﬂux. The lipid ﬁlm was
vacuum-desiccated overnight and subsequently resuspended in
phosphate buffer to a ﬁnal concentration. The lipid suspension
was bath-sonicated for 1 h to obtain the small unilamellar lipid
vesicles (SUVs). The vesicle samples were used immediately after
preparation.
2.4. Thioﬂavin-T ﬂuorescence assay
The Thioﬂavin-T ﬂuorescence assays were performed on a ﬂuo-
rescence spectrophotometer RF-530 LPC using a 440 nm excitation
ﬁlter and a 482 nm emission ﬁlter at room temperature without
shaking. In the absence of inhibitor, the assays were started imme-
diately after diluting hIAPP solution freshly prepared in 60 lL
Milli-Q water at 4 C using either buffer or freshly prepared SUV
solution. For assays of inhibition, freshly prepared buffer solution
of inhibitor was mixed with freshly prepared water solution of hIA-
PP at 4 C followed by the addition of either buffer or freshly
prepared SUV solution and immediately afterwards the measure-
ments were started. The concentrations of 15 lM hIAPP and
20 lM ThT were used for all ﬂuorescence assays. The lipid concen-
tration of 2.25 mM (lipid:hIAPP = 150:1) was used for the ﬂuores-
cence assays of SUV samples.
2.5. Transmission electron microscopy
The samples of 5 lL used for ThT assays were spotted on a 300-
mesh Formvar-carbon coated copper grid for 2 min. After washed
twice with 10 lL Milli-Q water the sample were air-dried over-
night and stained with 1% freshly prepared uranyl formate. Images
were recorded on JEM-2100F transmission electron microscope
operating at an accelerating voltage of 200 kV.
2.6. Far-ultraviolet circular dichroism
Far-UV CD spectra were recorded on a PMS-450 spectropolar-
imeter at room temperature under a constant ﬂow of N2. A quartz
cuvette with a path length of 0.1 mm was used. Data were
recorded from 260 to 190 nm with a 1 nm sampling interval. The
samples used in CD experiments were prepared similarly to those
used in ThT assays excluding addition of ThT dye. The ﬁnal concen-
trations of peptide and lipid were 24 lM and 3.6 mM (lipid:hIA-
PP = 150:1), respectively.
2.7. Dynamic light scattering (DLS) measurements
The DLS experiments were performed on a Zetasizer Nano-ZS
(Malvern Instruments) using a light scattering of 90 angle. The
particle size distribution of 15 lM hIAPP in buffer and POPC/POPG
(7:3) SUVs incorporated with 15 lM hIAPP at a peptide-lipid-ratio
of 1:150 in buffer was determined in the absence and presence of
D-NFGAIL. The freshly prepared samples were ﬁltered using
0.22 lm ﬁlters ﬁrstly and used to DLS measurements immediately.
The Dispersion Technology Software (DTS, V6.01) were applied for
data collection and analysis.
2.8. Atomic force microscopy
Peptides were dissolved in Milli-Q water at 4 C and mixed with
freshly prepared SUV solution (POPC:POPG 7:3) at a molar ratio of
lipid:hIAPP 25:1. The hIAPP/lipid mixture was incubated at room
temperature for 30 min. The liposomes of 20 lL were then
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at 65 C for 5 min to promote fusion and formation of planar lipid
bilayers [40]. All images were recorded using SPA-300 AFM instru-
ment in a contact mode.
2.9. Cell toxicity assays
INS-1 cells were grown in RPMI-1640 supplemented with 10%
(v/v) FBS, 50 U/ml penicillin, 50 lg/ml streptomycin and
50 lmol/l b-mercaptoethanol. Cells were seeded in 96-well plate
at a density of 1  104 cells/well and incubated at 37 C in 5%
CO2 atmosphere for 24 h. The media were aspirated and replaced
with fresh media with 15 lM hIAPP and/or different concentration
of inhibitor. Following 20 h incubation, 15 lL MTT were added to
each well and incubated for another 4 h. The absorbances were
measured by a microplate spectrometer reader at 540 nm.
3. Results and discussion
3.1. The inhibition of amyloid formation in bulk solution
Firstly, we examined the inhibitory effect of the all-D-amino-
acid inhibitor on the assembly of hIAPP in bulk solution. Similarly
to the results of previous studies [30], an aggregation process from
unstructured monomers to b-sheeted ﬁbrils was observed for hIA-
PP alone in bulk solution, as indicated by the time-dependence of
Thioﬂavin-T (ThT) ﬂuorescence, transmission electron microscopy
(TEM) image and circular dichroism (CD) spectra (Fig. 1A–C). The
addition of equimolar peptide inhibitor in bulk solution of hIAPP
resulted in a complete suppression of ThT ﬂuorescence intensity
(Fig. 1A) and disappearance of ﬁbrils in TEM image where only
small pieces with length around 200–300 nm were left (Fig. 1D).
The CD spectra of hIAPP in bulk solution with inhibitor were
similar to those of hIAPP alone (Fig. 1E), indicating that theFig. 1. The aggregation behaviors of hIAPP in bulk solution with and without D-NFGAIL: (
mixture of hIAPP and D-NFGAIL, (B) the TEM image of hIAPP alone after 48 h incubation,
1:1 mixture of hIAPP and D-NFGAIL after 48 h incubation, (E) the CD spectra of hIAPP w
image is 500 nm.conformational conversion from random coils to b-sheeted aggre-
gates still occurs in the presence of inhibitor, but the growth of
aggregates may be blocked by the inhibitor at a stage of b-sheeted
oligomeric intermediates.
In order to conﬁrm the difference in the dimensions of the
aggregate species of hIAPP in bulk solution with and without inhib-
itor, we measured the size population in the process of hIAPP
aggregation by the dynamic light scattering (DLS) experiments in
both cases (Fig. 2). In the absence of inhibitor, the growth of hIAPP
particles from hydrodynamic diameter (d) of several nanometers
(monomers) to several micrometers via intermediates with d smal-
ler than 400 nmwas clearly observed, along with the broadening of
size distribution. In comparison with the case of hIAPP alone in
bulk solution, the growth of the peptide in the presence of equimo-
lar inhibitor stopped at 2 h with a narrower population of d
around 200–350 nm. The small pieces with this size scales were in-
deed observed in TEM image (Fig. 1D). Interestingly, the time point
of hIAPP oligomers stopping growth (at 2 h) in the presence of
inhibitor is just that of the b-sheet structure beginning to form
(see Fig. 1C and E). This may imply that the blocking of the inhib-
itor to the growth of hIAPP oligomers is associated with the forma-
tion of b-sheet structure. Once the b-sheet structure forms at
certain small region of the peptide, further prolongation of the
peptide aggregates is prevented by the inhibitor.
3.2. The inhibition of amyloid formation at membrane
We next examined the inhibitory effect of the all-D-amino-acid
inhibitor under phospholipid membrane condition. Before addition
of the inhibitor, the ThT ﬂuorescence intensity of hIAPP in lipid
vesicle solution displayed a rapid increase after ca. 5 min delay
(Fig. 3A), which is much less than that of hIAPP in bulk solution
(corresponding time needed in bulk solution was ca. 2 h). The
decrease in the lag time was attributed to the accelerating role ofA) the ThT monitored kinetic process of aggregation for hIAPP alone and 1:1 M ratio
(C) the CD spectra of hIAPP alone at varying incubation time, (D) the TEM image of a
ith D-NFGAIL at a 1:1 M ratio at varying incubation time. The scale bar in each TEM
Fig. 2. The particle size distribution of hIAPP alone (left) and 1:1 M ratio mixture of hIAPP and D-NFGAIL (right) in bulk solution at the indicated time points monitored by the
dynamic light scattering.
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has been well established [41].
When hIAPP was incubated with equimolar inhibitor, the ThT
ﬂuorescence was completely suppressed, suggesting an efﬁcient
blocking of the inhibitor to hIAPP ﬁbril formation at membrane
surface. The inhibition activity of the peptide inhibitor to hIAPPﬁbrillation observed in ThT binding assays (Fig. 3A) was conﬁrmed
by atomic force microscopy (AFM) images. As show in Fig. 3B–D,
whereas abundant ﬁbrils were formed at lipid membrane in the
absence of the inhibitor, the amyloid ﬁbrils were remarkably
decreased when hIAPP was incubated with equimolar inhibitor.
The ﬁbrillation was even completely inhibited and a large amount
Fig. 3. The aggregation behaviors of hIAPP at membrane surface with and without D-NFGAIL: (A) the ThT monitored kinetic process of aggregation for hIAPP alone and 1:1 M
ratio mixture of hIAPP and D-NFGAIL (lipid:hIAPP 150:1), (B) AFM images of hIAPP aggregates formed without D-NFGAIL, (C) with equimolar D-NFGAIL and (D) threefold D-
NFGAIL (lipid:hIAPP 25:1). All images were detected after incubation for 30 min. at room temperature. Scale bars in the images are 1 lm.
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was noted that very thin and elongated ﬁbers are clearly present
in AFM image at a molar ratio of hIAPP:inhibitor = 1:1 but there
is no observable increase in the ﬂuorescence intensity at the same
hIAPP:inhibitor ratio. This was because the ﬂuorescence experi-
ments were performed at a molar ratio of lipid:hIAPP = 150:1,
while the ratio used in AFM experiments was 25:1. Lower
lipid:hIAPP ratio (or higher concentration of hIAPP at membrane
surface) used in the AFM experiments caused more rapid aggrega-
tion of hIAPP and thus less effective inhibition for ﬁbril formation.
We also measured the AFM image of the inhibitor alone in the
presence of phospholipids after the same incubation time (see
Fig. S1 in the Supporting Information). No any apparent aggregates
were observed on the AFM image, conﬁrming that the oligomers
appearing in the AFM image of hIAPP in the presence of inhibitor
result from the amyloid peptides but not the inhibitor.
The DLS measurements of hIAPP incorporated SUVs were car-
ried out in the absence and presence of inhibitor to provide further
evidence of the peptide aggregation at membrane surface and the
effective inhibition of the ﬁbrillation by the all-D-amino-acid inhib-
itor (see Figs. S2 and S3 in the Supporting Information). Immedi-
ately after preparation, the hIAPP incorporated SUVs in the
absence of inhibitor displayed a distribution of particle size around
d of 40 nm. The d increased to 200 nm after 15 min incubation,
and then another population of particle size around d of 5 lm ap-
peared. In contrast, there was only one population of particles for
the hIAPP incorporated SUVs with 1:3 M ratio of hIAPP/inhibitor
through the entire incubation time of 1 h. The d increased from
45 to 100 nm before 15 min incubation and remained at
150 nm after 15 min incubation. This indicates that the amyloid
peptide aggregates rapidly at SUV surface in the absence of inhib-
itor and the aggregation is effectively blocked in the presence of
inhibitor. Although the DLS experiments conﬁrm the aggregation
of hIAPP at SUV surface and the inhibition of ﬁbrillation by the
inhibitor, the sizes of particles observed in DLS could not be
compared directly with AFM observation. The DLS provides theestimation of the sizes of the complexes of SUVs with various mor-
phologies of hIAPP (monomers, oligomers or proﬁbrils/ﬁbrils),
whereas the AFM image displays the real sizes of hIAPP oligomers
or clusters of the oligomers.
The CD spectra of hIAPP alone in lipid vesicle solution displayed
two negative absorbance bands at ca. 208 and 222 nm for a freshly
prepared sample and a single negative absorbance band at ca.
218 nm after 30 min incubation (Fig. 4). The results suggest that
the hIAPP molecules form an a-helix structure at lipid membrane
surface at the initial stage of aggregation, and the helicity keeps
before 30 min incubation time and then the conformational con-
version from a-helix to b-sheet occurs. The initial helical state of
membrane-binding hIAPP may be an equilibrium existence of
monomeric form and heterogeneous aggregates, as suggested by
the study of hIAPP bound with DOPG (1,2-dioleoyl-sn-glycero-3-
(phospho-rac-1-glycerol)) [24].
The CD spectra of hIAPP in lipid vesicle solution containing the
peptide inhibitor also displayed a characteristic of a-helix struc-
ture with two negative absorbance bands at ca. 208 and 222 nm
at the beginning stage of hIAPP aggregation. Interestingly, the a-
helix structure of hIAPP was still maintained after 1 h incubation
in the presence of either equimolar or 3-fold inhibitor (Fig. 4). This
suggests that there may be a morphological conversion of hIAPP
from a-helix monomers to a-helix-containing aggregates before
formation of b-sheet aggregates at lipid membrane surface [24]
and the inhibitor can stabilize the membrane-induced a-helix-con-
taining oligomers, block their further conversion to b-sheet aggre-
gates and consequently prevent the formation of amyloid ﬁbrils
effectively (Fig. 5). Our results support the ﬁbril formation mecha-
nism in which the a-helical aggregate state is on-pathway of
ﬁbrillogenesis.
It is worthy of note that the predominant resultants of hIAPP
inhibition are the b-sheet binding intermediates in bulk solution,
but not the a-helical folding intermediates like those formed at
membrane surface. This indicates that the inhibitor prevents the
hIAPP ﬁbril formation in bulk solution by a mechanism different
Fig. 5. Proposed mechanism of the inhibitor D-NFGAIL inhibiting the ﬁbril formation of hIAPP at lipid membrane.
Fig. 4. The time-dependent CD spectra of hIAPP incorporated with SUVs in the absence of D-NFGAIL (A), and in the presence of equimolar (B) and threefold (C) D-NFGAIL.
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trapped at membrane surfaces but not in bulk solution perhaps
due to the stabilizing effect of lipid membranes on the helical
conformation that provides more chances for inhibitor to interact
with the intermediate species and block their conformational
rearrangement and/or further aggregation.3.3. The inhibition effect in cells
Finally, we measured the cellular viability in INS-1 cells using
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assays to evaluate the effect of the inhibitor on hIAPP-
induced cytotoxicity. A signiﬁcant cytotoxicity was observed for
890 L. Wang et al. / FEBS Letters 588 (2014) 884–89115 lM hIAPP alone incubated for 24 h. The cell viability of hIAPP
alone was 56%. The presence of an equimolar amount of the
all-D-amino-acid inhibitor decreased the cytotoxicity of hIAPP
and increased the cell viability to 63% (Fig. 6). Further increase in
the ratio of inhibitor to hIAPP to 3:1 resulted in a considerable rise
in cell viability (to 85%). When the molar ratio of inhibitor to hIAPP
was increased to 20:1, the cell viability approached to 95%. Control
experiments treated with inhibitor alone displayed that the
all-D-amino-acid inhibitor itself has no cytotoxicity at tested
concentrations (see Fig. S4 in the Supporting Information). The cell
viability of hIAPP in the presence of varying concentrations of
all-D-amino-acid inhibitor is well in agreement with the inhibition
efﬁciency at phospholipid membrane.
The MTT-based assay showed that the cell viability is efﬁciently
increased rather than decreased by addition of the all-D-amino-
acid inhibitor in cell culture media including hIAPP, suggesting that
the inhibition resultants from the all-D-amino-acid inhibitor are
not cytotoxic. However, what kinds of inhibition resultants are
formed or how the presence of the inhibitor decreases the cytotox-
icity of hIAPP in the cellular membrane is unclear. Our study at
phospholipid membrane suggests a possible mechanism of the
all-D-amino-acid inhibitor blocking ﬁbrillation of hIAPP at cellular
membrane in which the a-helical intermediates are targeted. In
the previous study, the oligomeric intermediates of hIAPP have
been shown to be more cytotoxic than the mature amyloid ﬁbrils
[42]. The observation in the present study implies that the binding
of the all-D-amino-acid inhibitor with hIAPP oligomeric intermedi-
ates inhibits the cytotoxicity. The study of Sellin et al. on the inhi-
bition of hIAPP ﬁbrillation at lipid membrane surface has
demonstrated that the interaction of hIAPP with lipid membrane
can be completely abolished in the presence of NFGAIL-GI, a pep-
tide inhibitor from the N-methylation of the backbone amides at
G and I of NFGAIL, and the sequestration of hIAPP in the aqueous
phase was accounted for the observed strong inhibitory effect of
NFGAIL-GI on hIAPP ﬁbrillization [11]. The same thing may happen
in our study. The complexes of the inhibitor and hIAPP oligomeric
intermediates cannot be absorbed at lipid membrane or the inter-
action of the hIAPP intermediates with membrane is disrupted by
the binding of the inhibitor with the oligomers, which results in
the solubilization of the inhibitor-bound intermediates into aque-
ous phase and the decrease in cytotoxicity.
In conclusion, the results in the current study suggest a novel
and highly potential all-D-amino-acid inhibitor D-NFGAIL used
for inhibiting hIAPP ﬁbrillation and demonstrate its inhibitory efﬁ-
ciency at phospholipid membrane surface by targeting helical olig-
omeric intermediates and effective protection for cells against
hIAPP-induced toxicity. The inhibitor also has high potency toFig. 6. Cell viability of INS-1 cells treated with hIAPP in the absence and presence of
D-NFGAIL (⁄⁄⁄P < 0.001 vs. Control group, ##P < 0.01 vs. hIAPP-treaded group,
###P < 0.001 vs. hIAPP-treated group).inhibit the formation of hIAPP amyloid ﬁbrils in bulk solution.
However, the mechanism of inhibition in bulk solution is different
from that at membrane surface. The inhibitor terminates hIAPP
aggregation at b-sheeted oligomeric intermediates in bulk solution,
instead of a-helical intermediates. Our results show an evidence
for the actual existence of a-helical oligomers as crucial intermedi-
ates on the pathway of hIAPP ﬁbrillation at membrane surface and
the ﬁrst example of inhibitor that blocks the ﬁbril formation of
amyloid protein by targeting helical intermediates. This study
could provide a new idea for designing the inhibitors of amyloid
proteins.
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